GlobeNewswire by notified

Nordic American Tankers Ltd (NYSE: NAT) – NAT is in an expansionary mode based on concrete projects

Share


Wednesday, July 28, 2021

Dear Shareholders and Investors, 

A few years ago, NAT winnowed its fleet from 33 vessels to 23 vessels. Last year the company ordered two newbuildings from South Korea. These two ships will be delivered to NAT in 2022. As described below the path forward is expansion. We have concrete projects to sell at least two ships built in 2000 and 2002. These sales are a part of a process to increase the fleet by purchasing at least two or more additional ships of a more recent vintage than the ones that will be sold. These strategic moves will strengthen NAT substantially. 

It is an important objective for NAT to prioritize dividend. This policy is steadfast. It is linked to the market for our 25 suezmax tankers.  In a strong tanker market higher dividends will be produced than in a weak market.

A second goal is to facilitate the sale and purchase of the NAT stock. An investor wishing to buy the NAT stock should be able to do so easily. Conversely, an investor wishing to sell his NAT portfolio (partly or wholly) should have the opportunity to do so. The expert expression is that NAT is providing for a large free float in the stock.

A third element is the importance of our brand and what we stand for. We wish to communicate the values of NAT, which include integrity, reliability, customer focus, sustainablity and a completely corruption free approach. In the past we have left trading areas for our ships because conditions in these areas did not meet our commitment to our values. 

The objective for NAT is to become more or less debt free as was the NAT position in the past. As one of the largest New York listed tanker companies, NAT’s focus must be on shareholders and on investors.   

Thus, at this time we shall renew and expand our fleet as explained above. Now, it is a good time to implement these projects.

Sincerely,

Herbjorn Hansson
Founder, Chairman & CEO

Nordic American Tankers Ltd.                                                           www.nat.bm  

 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intend,” “estimate,” “forecast,” “project,” “plan,” “potential,” “will,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand in the tanker market, as a result of changes in OPEC’s petroleum production levels and worldwide oil consumption and storage, changes in our operating expenses, including bunker prices, drydocking and insurance costs, the market for our vessels, availability of financing and refinancing, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other important factors described from time to time in the reports filed by the Company with the Securities and Exchange Commission, including the prospectus and related prospectus supplement, our Annual Report on Form 20-F, and our reports on Form 6-K.

NAT is a New York listed company based in Bermuda.

Contacts:    

Gary J. Wolfe
Seward & Kissel LLP
New York, USA
Tel: +1 212 574 1223

Bjørn Giæver, CFO                                                             
Nordic American Tankers Ltd                                             
Tel: +1 888 755 8391 or +47 91 35 00 91                                 

Herbjørn Hansson, Founder, Chairman & CEO
Nordic American Tankers Ltd
Tel: +1 866 805 9504 or +47 90 14 62 91       


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding

Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release

Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release

Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and

Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 202419.4.2024 17:00:00 CEST | Press release

Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive programs (the “LTIP”) for Zealand's Board of Directors, Corporate Management and employees in accordance with Zealand's remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on March 20, 2024 (“Remuneration Policy”). Long-term incentive program Zealand has made the following awards in its long-term incentive plan. It has awarded: 20,497 restricted stock units ("RSUs") to Zealand's Board of Directors 52,777 performance stock units ("PSUs") and 52,777 RSUs have been awarded to Zealand’s Corporat

Dr. Sam Barrell CBE appointed as CEO of LifeArc19.4.2024 17:00:00 CEST | Press release

PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam’s appointment follows an extensive international recruitment process. Sam will join LifeArc from the Francis Crick Institute where she is currently Deputy CEO with responsibility for strategic management and operational leadership, as well as deputising for the Director, Sir Paul Nurse. She joined the Crick in 2017 as Chief Operating Officer. Sam brings over 25 years of experience in the life science and healthcare sectors, and a wealth of knowledge of the activities in commercial, digital and health tech spaces which are critical to LifeArc’s strategy. She studied medicine, training as an anaesthetist and serving in General Practice for many years, and has held a number of senior leadership positions in the NHS, most recently as CEO of Taunton and Somerset NHS Foundation Trust. She

HiddenA line styled icon from Orion Icon Library.Eye